专题：Spondyloarthritis Studies and Treatments

This cluster of papers focuses on the classification, diagnosis, and treatment of spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis. It covers the development of new classification criteria, assessment of disease activity, use of biologic therapies such as tumor necrosis factor inhibitors and interleukin-17 inhibitors, and the impact of genetic factors like HLA-B27.
最新文献
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity

article Full Text OpenAlex

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

article Full Text OpenAlex

Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints

article Full Text OpenAlex

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

review Full Text OpenAlex

Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative

review Full Text OpenAlex

The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies

review Full Text OpenAlex

The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review

review Full Text OpenAlex

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

article Full Text OpenAlex

Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites

article Full Text OpenAlex

EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis

article Full Text OpenAlex

近5年高被引文献
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

article Full Text OpenAlex 1003 FWCI139.2063

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

review Full Text OpenAlex 630 FWCI21.5588

Signaling pathways and targeted therapies for psoriasis

review Full Text OpenAlex 437 FWCI12.2208

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

article Full Text OpenAlex 388 FWCI126.0993

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

article Full Text OpenAlex 377 FWCI28.628

The Immunology of Psoriasis—Current Concepts in Pathogenesis

review Full Text OpenAlex 345 FWCI15.3156

Challenges and Future Trends in the Treatment of Psoriasis

review Full Text OpenAlex 320 FWCI8.9285

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

article Full Text OpenAlex 303 FWCI23.2662

Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis

article Full Text OpenAlex 288 FWCI31.595

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

review Full Text OpenAlex 231 FWCI5.0908